EUVIMEDEUVIMED entdecken
Crossref

Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series

Rahul S Dalal iD, Lindsay M Clarke iD, Heidy J Cabral, Alexander D Carlin, Grace B Hardwick, Jessica R Allegretti

Alimentary Pharmacology & Therapeutics · 2025-11 · 62 (10) · 1023-1026

DOI: 10.1111/apt.70298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 24.07.2025. Verfasst von Rahul S Dalal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massach…. Hauptthemen laut MEDLINE: Crohn Disease, Antibodies, Monoclonal, Humanized, Infliximab, Ustekinumab. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 4 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combining two advanced therapies may improve outcomes in Crohn's disease (CD) refractory to monotherapy. We conducted a descriptive case series of 27 patients with CD who initiated combination therapy with upadacitinib and infliximab ( n = 1), risankizumab ( n = 17), ustekinumab ( n = 3) or vedolizumab ( n = 6). At 12 weeks, 24 achieved clinical response and 9 achieved steroid‐free remission. At 52 weeks, these rates were 15/20 and 11/20, respectively. Endoscopic response and extraintestinal manifestation improvement were frequently observed. Adverse events occurred in 13 patients, leading to treatment discontinuation in three. Combining upadacitinib with a biologic appeared effective and safe, warranting further investigation in prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseAntibodies, Monoclonal, HumanizedInfliximabUstekinumabHeterocyclic Compounds, 3-RingGastrointestinal AgentsAntibodies, MonoclonalHumansFemaleMaleAdultDrug Therapy, CombinationMiddle AgedTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

advanced therapybiologiccombination therapydual therapyinflammatory bowel disease

Substanzen

Antibodies, Monoclonal, HumanizedvedolizumabInfliximabUstekinumabHeterocyclic Compounds, 3-RingupadacitinibrisankizumabGastrointestinal AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Rahul S Dalal, Lindsay M Clarke

Zitieren

APA

Dalal, R. S., Clarke, L. M., Cabral, H. J., Carlin, A. D., Hardwick, G. B., & Allegretti, J. R. (2025). Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series. Alimentary Pharmacology & Therapeutics, 62(10), 1023-1026. https://doi.org/10.1111/apt.70298

Vancouver

Dalal RS, Clarke LM, Cabral HJ, Carlin AD, Hardwick GB, Allegretti JR. Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series. Alimentary Pharmacology & Therapeutics. 2025;62(10):1023-1026. doi:10.1111/apt.70298

BibTeX
@article{Dalal2025,
  author = {Dalal, Rahul S and Clarke, Lindsay M and Cabral, Heidy J and Carlin, Alexander D and Hardwick, Grace B and Allegretti, Jessica R},
  title = {Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {62},
  number = {10},
  pages = {1023--1026},
  doi = {10.1111/apt.70298}
}
Kostenlos starten →